{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:17:07Z","timestamp":1767651427449},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s11886-021-01453-y","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T22:02:44Z","timestamp":1614722564000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Medical Therapy Versus Revascularization in Patients with Stable Ischemic Heart Disease and Advanced Chronic Kidney Disease"],"prefix":"10.1007","volume":"23","author":[{"given":"Timir K.","family":"Paul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamas A.","family":"Mamas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhan","family":"Shanmugasundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsha S.","family":"Nagarajarao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandra P.","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Jneid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"1453_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0735-1097(02)02663-3","volume":"41","author":"G Manjunath","year":"2003","unstructured":"Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"1453_CR2","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073\u201381.","journal-title":"Lancet"},{"key":"1453_CR3","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(12)61272-0","volume":"380","author":"BK Mahmoodi","year":"2012","unstructured":"Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380:1649\u201361.","journal-title":"Lancet"},{"key":"1453_CR4","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296\u2013305.","journal-title":"N Engl J Med"},{"key":"1453_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamainternmed.2015.6102","volume":"176","author":"I Konstantinidis","year":"2016","unstructured":"Konstantinidis I, Nadkarni GN, Yacoub R, et al. Representation of patients with kidney disease in trials of cardiovascular Interventions: an updated systematic review. JAMA Intern. Med. 2016;176:121\u20134.","journal-title":"JAMA Intern. Med."},{"issue":"17","key":"1453_CR6","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.jacc.2017.02.001","volume":"69","author":"MR Patel","year":"2017","unstructured":"Patel MR, Calhoon JH, Dehmer GJ, et al. ACC\/AATS\/AHA\/ASE\/ASNC\/SCAI\/SCCT\/STS 2017 Appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for T. J Am Coll Cardiol. 2017;69(17):2212\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"1453_CR7","first-page":"e354","volume":"126","author":"SD Fihn","year":"2012","unstructured":"Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart diseass. Circulation. 2012;126(25):e354\u2013471.","journal-title":"Circulation"},{"issue":"3","key":"1453_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Achenbach S, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407\u201377.","journal-title":"Eur Heart J"},{"issue":"1","key":"1453_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/jcm9010004","volume":"9","author":"E Vidal-Petiot","year":"2019","unstructured":"Vidal-Petiot E, Greenlaw N, Kalra PR, et al. Chronic kidney disease has a graded association with death and cardiovascular outcomes in stable coronary artery disease: An Analysis of 21,911 Patients from the CLARIFY Registry. J Clin Med. 2019;9(1):4.","journal-title":"J Clin Med"},{"issue":"3","key":"1453_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","volume":"45","author":"C Baigent","year":"2005","unstructured":"Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45(3):473\u201384.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1453_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000080241","volume":"27","author":"C Wanner","year":"2004","unstructured":"Wanner C, Krane V, M\u00e4rz W, et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res. 2004;27(4):259\u201366.","journal-title":"Kidney Blood Press Res"},{"issue":"14","key":"1453_CR12","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstr\u00f6m","year":"2009","unstructured":"Fellstr\u00f6m BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395\u2013407.","journal-title":"N Engl J Med"},{"issue":"5","key":"1453_CR13","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ahj.2010.08.012","volume":"160","author":"C Baigent","year":"2010","unstructured":"Baigent C, Landray M, Reith C, et al. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J [Internet. 2010;160(5):785\u201394.","journal-title":"Am Heart J"},{"issue":"9784","key":"1453_CR14","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392.","journal-title":"Lancet"},{"issue":"3","key":"1453_CR15","first-page":"1","volume":"3","author":"MA Tonelli","year":"2013","unstructured":"Tonelli MA, Wanner C, Cass A, et al. Kidney Disease: Improving Global Outcomes (KDIGO) lipid work group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3(3):1\u2013315.","journal-title":"Kidney Int Suppl"},{"key":"1453_CR16","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","volume":"73","author":"DM Charytan","year":"2019","unstructured":"Charytan DM, Sabatine MS, Pedersen TR, et al. Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER Trial. J Am Coll Cardiol. 2019;73:2961\u201370.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"1453_CR17","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1056\/NEJMoa1915925","volume":"382","author":"S Bangalore","year":"2020","unstructured":"Bangalore S, Maron DJ, O\u2019Brien SM, et al. Management of coronary disease in patients with advanced kidney disease. N Engl J Med. 2020;382(17):1608\u201318 The results of this study show that among patients with stable coronary disease with moderate to severe ischemia and advanced chronic kidney disease, an initial invasive strategy did not reduce the risk of death or nonfatal myocardial infarction as compared with an initial conservative strategy.","journal-title":"N Engl J Med"},{"issue":"15","key":"1453_CR18","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"WE Boden","year":"2007","unstructured":"Boden WE, O\u2019Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503\u201316.","journal-title":"N Engl J Med"},{"key":"1453_CR19","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","volume":"360","author":"RL Frye","year":"2009","unstructured":"Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503\u201315.","journal-title":"N Engl J Med"},{"key":"1453_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.amjcard.2020.07.025","volume":"133","author":"Q Radaideh","year":"2020","unstructured":"Radaideh Q, Osman M, Kheiri B, et al. Meta-analysis of the effect of percutaneous coronary intervention on death and myocardial infarction in patients with stable coronary artery disease and inducible myocardial ischemia. Am J Cardiol. 2020;133:171\u20134 This meta-analysis of randomized trials in patients with stable ischemic heart disease and moderate to severe ischemia reveals that PCI was not associated with reducing all-cause mortality, cardiovascular mortality, or MI as compared to medical therapy.","journal-title":"Am J Cardiol"},{"issue":"12","key":"1453_CR21","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.amjcard.2009.07.043","volume":"104","author":"SP Sedlis","year":"2009","unstructured":"Sedlis SP, Jurkovitz CT, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. Am J Cardiol. 2009;104(12):1647\u201353.","journal-title":"Am J Cardiol"},{"key":"1453_CR22","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/j.amjcard.2013.07.034","volume":"112","author":"SP Sedlis","year":"2013","unstructured":"Sedlis SP, Jurkovitz CT, Hartigan PM, et al. Health status and quality of life in patients with stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post Hoc findings from the COURAGE trial). Am J Cardiol. 2013;112:1703\u20138.","journal-title":"Am J Cardiol"},{"issue":"12","key":"1453_CR23","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.amjmed.2016.06.046","volume":"129","author":"A Volodarskiy","year":"2016","unstructured":"Volodarskiy A, Kumar S, Amin S, Bangalore S. Optimal treatment strategies in patients with chronic kidney disease and coronary artery disease. Am J Med. 2016;129(12):1288\u201398.","journal-title":"Am J Med"},{"issue":"4","key":"1453_CR24","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/ehjqcco\/qcx042","volume":"4","author":"JS Shavadia","year":"2018","unstructured":"Shavadia JS, Southern DA, James MT, Welsh RC, Bainey KR. Kidney function modifies the selection of treatment strategies and long-term survival in stable ischaemic heart disease: Insights from the Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) registry. Eur Hear J - Qual Care Clin Outcomes. 2018;4(4):274\u201382.","journal-title":"Eur Hear J - Qual Care Clin Outcomes"},{"issue":"15","key":"1453_CR25","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","volume":"382","author":"DJ Maron","year":"2020","unstructured":"Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382(15):1395\u2013407 Among patients with stable coronary disease and moderate or severe ischemia, there was no evidence that an initial invasive strategy reduced the risk of ischemic cardiovascular events or death from any cause as compared with an initial conservative strategy.","journal-title":"N Engl J Med"},{"issue":"17","key":"1453_CR26","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1056\/NEJMoa1916374","volume":"382","author":"JA Spertus","year":"2020","unstructured":"Spertus JA, Jones PG, Maron DJ, et al. Health status after invasive or conservative care in coronary and advanced kidney disease. N Engl J Med. 2020;382(17):1619\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"1453_CR27","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/ccd.22562","volume":"76","author":"A Abdel-Latif","year":"2010","unstructured":"Abdel-Latif A, Mukherjee D, Mesgarzadeh P, et al. Drug-eluting stents in patients with end-stage renal disease: meta-analysis and systematic review of the literature. Catheter Cardiovasc Interv. 2010;76(7):942\u20138.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1453_CR28","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1161\/CIRCULATIONAHA.112.001264","volume":"127","author":"GR Shroff","year":"2013","unstructured":"Shroff GR, Solid CA, Herzog CA. Long-term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the united states. Circulation. 2013;127:1861\u20139.","journal-title":"Circulation"},{"key":"1453_CR29","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1161\/CIRCULATIONAHA.105.580084","volume":"113","author":"WA Cooper","year":"2006","unstructured":"Cooper WA, O\u2019Brien SM, Thourani VH, et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation. 2006;113:1063\u201370.","journal-title":"Circulation."},{"issue":"3","key":"1453_CR30","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ahj.2004.10.010","volume":"149","author":"JH Ix","year":"2005","unstructured":"Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the arterial revascularization therapies study (ARTS). Am Heart J. 2005;149(3):512\u20139.","journal-title":"Am Heart J"},{"issue":"4","key":"1453_CR31","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ. Res. 2018;122(4):624\u201338.","journal-title":"Circ. Res."},{"issue":"3","key":"1453_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/HPC.0b013e31825d267a","volume":"11","author":"S Kersting","year":"2012","unstructured":"Kersting S, Grumann T, Hummel J, et al. Impact of chronic kidney disease on long-term clinical outcomes after percutaneous coronary intervention with drug-eluting or bare-metal stents. Crit Pathw Cardiol. 2012;11(3):152\u20139.","journal-title":"Crit Pathw Cardiol"},{"issue":"3","key":"1453_CR33","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.amjcard.2010.03.037","volume":"106","author":"G Ashrith","year":"2010","unstructured":"Ashrith G, Lee VV, Elayda MA, Reul RM, Wilson JM. Short- and long-term outcomes of coronary artery bypass grafting or drug-eluting stent implantation for multivessel coronary artery disease in patients with chronic kidney disease. Am J Cardiol. 2010;106(3):348\u201353.","journal-title":"Am J Cardiol"},{"issue":"3","key":"1453_CR34","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4070\/kcj.2016.0439","volume":"47","author":"SH Kang","year":"2017","unstructured":"Kang SH, Lee CW, Yun SC, et al. Coronary artery bypass grafting vs. drug-eluting stent implantation for multivessel disease in patients with chronic kidney disease. Korean Circ J. 2017;47(3):354\u201360.","journal-title":"Korean Circ J"},{"key":"1453_CR35","doi-asserted-by":"publisher","first-page":"12091220","DOI":"10.1016\/j.jacc.2015.06.1334","volume":"66","author":"S Bangalore","year":"2015","unstructured":"Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Revascularization in patients with multivessel coronary artery disease and chronic kidney disease everolimus-eluting stents versus coronary artery bypass graft surgery. J Am Coll Cardiol. 2015;66:12091220.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"1453_CR36","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/eurheartj\/ehi288","volume":"26","author":"J Aoki","year":"2005","unstructured":"Aoki J, Ong ATL, Hoye A, et al. Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease: insights from ARTS trial. Eur Heart J. 2005;26(15):1488\u201393.","journal-title":"Eur Heart J"},{"issue":"46","key":"1453_CR37","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1093\/eurheartj\/ehw378","volume":"37","author":"U Baber","year":"2016","unstructured":"Baber U, Farkouh ME, Arbel Y, et al. Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes andmultivessel coronary artery disease with or without chronic kidney disease. Eur Heart J. 2016;37(46):3440\u20137.","journal-title":"Eur Heart J"},{"key":"1453_CR38","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.kint.2016.03.033","volume":"90","author":"DM Charytan","year":"2016","unstructured":"Charytan DM, Desai M, Mathur M, et al. Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease. Kidney Int. 2016;90:411\u201321.","journal-title":"Kidney Int"},{"issue":"4","key":"1453_CR39","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jacc.2018.11.044","volume":"73","author":"ME Farkouh","year":"2019","unstructured":"Farkouh ME, Sidhu MS, Brooks MM, et al. Impact of chronic kidney disease on outcomes of myocardial revascularization in patients with diabetes. J Am Coll Cardiol. 2019;73(4):400\u201311.","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-021-01453-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-021-01453-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-021-01453-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T03:48:11Z","timestamp":1618372091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-021-01453-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1453"],"URL":"https:\/\/doi.org\/10.1007\/s11886-021-01453-y","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"18 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no financial relationships or conflicts of interest regarding the content herein.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"23"}}